West Pharmaceutical Services, I vs Becton, Dickinson and Company
A head-to-head of West Pharmaceutical Services, I (WST) and Becton, Dickinson and Company (BDX) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | WST | BDX |
|---|---|---|
| Market Cap | $25.31B | $43.58B |
| P/E (TTM) | 47.79 | 27.18 |
| Forward P/E | 34.01 | 10.93 |
| P/S | 6.48 | 1.82 |
| P/B | 8.67 | 2.43 |
| EV/EBITDA | 24.06 | 9.25 |
| Dividend Yield | 0.24% | 2.02% |
| Profit Margin | 16.85% | 5.33% |
| Gross Margin | 35.89% | 45.44% |
| Operating Margin | 20.09% | 13.67% |
| Revenue Growth (YoY) | +21.01% | +5.22% |
| FCF Yield | 2.19% | 7.55% |
| Debt / Equity | 7.50 | 71.60 |
| Current Ratio | 2.71 | 0.94 |
Which is better: West Pharmaceutical Services, I or Becton, Dickinson and Company?
- ✓Larger by market cap: Becton, Dickinson and Company
- ✓Cheaper valuation (lower P/E): Becton, Dickinson and Company
- ✓Higher dividend yield: Becton, Dickinson and Company
- ✓More profitable (net margin): West Pharmaceutical Services, I
- ✓Faster revenue growth: West Pharmaceutical Services, I
- ✓Higher free-cash-flow yield: Becton, Dickinson and Company
Across 13 available metrics, Becton, Dickinson and Company leads 8–5.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.